Cargando…

Intralesional Vitamin D3 Versus Bleomycin for Difficult-to-Heal Palmoplantar Warts: A Comparative Study

INTRODUCTION: Difficult-to-heal or recalcitrant palmoplantar warts are notoriously resistant to treatment, making treatment difficult and challenging. To improve the outcome and overcome the difficulties, various treatment options have been tried, but none is gold standard. Many comparative studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Prathibha, Jantikolalu Parameswarappa, Varghese, Nidhin, Aithal, Vijay Venkatraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405549/
https://www.ncbi.nlm.nih.gov/pubmed/37554676
http://dx.doi.org/10.4103/JCAS.JCAS_128_21
_version_ 1785085556770734080
author Prathibha, Jantikolalu Parameswarappa
Varghese, Nidhin
Aithal, Vijay Venkatraj
author_facet Prathibha, Jantikolalu Parameswarappa
Varghese, Nidhin
Aithal, Vijay Venkatraj
author_sort Prathibha, Jantikolalu Parameswarappa
collection PubMed
description INTRODUCTION: Difficult-to-heal or recalcitrant palmoplantar warts are notoriously resistant to treatment, making treatment difficult and challenging. To improve the outcome and overcome the difficulties, various treatment options have been tried, but none is gold standard. Many comparative studies have been undertaken to assess the efficacy of various drugs; however, none of them are standardized, and no single treatment is effective. Various comparative efficacy studies have been conducted but, to the best of our knowledge, no study has been conducted comparing intralesional (IL) injection (inj) vitamin D3 (Vit D3) with the chemotherapy drug IL inj Bleomycin for difficult-to-heal palmoplantar warts. We conducted a trial to evaluate the efficacy of IL inj Vit D3 versus IL inj Bleomycin in the treatment of difficult-to-heal palmoplantar warts. The purpose of this study was to compare the efficacy of IL inj vitamin D3 versus IL inj Bleomycin as biological response modifier therapy in difficult-to-heal palmoplantar warts. MATERIALS AND METHODS: A cohort of 48 patients with difficult-to-heal warts were consecutively assigned to one of two groups: Group 1 IL inj Vit D3 (0.2–0.5 mL inj vitamin D3 600,000 IU solution 15 mg/mL) or Group 2 IL inj Bleomycin (0.2–0.4 mL of 1 U/mL solution) for a maximum of four treatments spaced 2 weeks apart, with a maximum of five warts treated at each visit for both groups. Warts were measured at baseline and at each subsequent visit. Wart’s resolution was measured as 1–25%, 2–50%, 3–75%, and 4–100% reduction. Patients were followed-up for 3 months after treatment. RESULTS: All the 48 patients completed the study, with 26 receiving IL inj Vit D3 with complete resolution in 88.5%, partial resolution in 11.5%, and side effects in 6.2%. In 22 patients receiving IL inj Bleomycin, 95.5% had complete resolution, 4.5% had partial resolution, and 8.2% had side effects. Maximum resolution was observed in the third session. We found no recurrence after 3 months. CONCLUSION: IL inj Vit D3 and IL inj Bleomycin are both safe and effective in treating difficult-to-heal palmoplantar warts with better outcomes and patient satisfaction. IL Bleomycin was significantly more effective than IL Vit D3, although the difference was not statistically significant.
format Online
Article
Text
id pubmed-10405549
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-104055492023-08-08 Intralesional Vitamin D3 Versus Bleomycin for Difficult-to-Heal Palmoplantar Warts: A Comparative Study Prathibha, Jantikolalu Parameswarappa Varghese, Nidhin Aithal, Vijay Venkatraj J Cutan Aesthet Surg Original Article INTRODUCTION: Difficult-to-heal or recalcitrant palmoplantar warts are notoriously resistant to treatment, making treatment difficult and challenging. To improve the outcome and overcome the difficulties, various treatment options have been tried, but none is gold standard. Many comparative studies have been undertaken to assess the efficacy of various drugs; however, none of them are standardized, and no single treatment is effective. Various comparative efficacy studies have been conducted but, to the best of our knowledge, no study has been conducted comparing intralesional (IL) injection (inj) vitamin D3 (Vit D3) with the chemotherapy drug IL inj Bleomycin for difficult-to-heal palmoplantar warts. We conducted a trial to evaluate the efficacy of IL inj Vit D3 versus IL inj Bleomycin in the treatment of difficult-to-heal palmoplantar warts. The purpose of this study was to compare the efficacy of IL inj vitamin D3 versus IL inj Bleomycin as biological response modifier therapy in difficult-to-heal palmoplantar warts. MATERIALS AND METHODS: A cohort of 48 patients with difficult-to-heal warts were consecutively assigned to one of two groups: Group 1 IL inj Vit D3 (0.2–0.5 mL inj vitamin D3 600,000 IU solution 15 mg/mL) or Group 2 IL inj Bleomycin (0.2–0.4 mL of 1 U/mL solution) for a maximum of four treatments spaced 2 weeks apart, with a maximum of five warts treated at each visit for both groups. Warts were measured at baseline and at each subsequent visit. Wart’s resolution was measured as 1–25%, 2–50%, 3–75%, and 4–100% reduction. Patients were followed-up for 3 months after treatment. RESULTS: All the 48 patients completed the study, with 26 receiving IL inj Vit D3 with complete resolution in 88.5%, partial resolution in 11.5%, and side effects in 6.2%. In 22 patients receiving IL inj Bleomycin, 95.5% had complete resolution, 4.5% had partial resolution, and 8.2% had side effects. Maximum resolution was observed in the third session. We found no recurrence after 3 months. CONCLUSION: IL inj Vit D3 and IL inj Bleomycin are both safe and effective in treating difficult-to-heal palmoplantar warts with better outcomes and patient satisfaction. IL Bleomycin was significantly more effective than IL Vit D3, although the difference was not statistically significant. Wolters Kluwer - Medknow 2023 /pmc/articles/PMC10405549/ /pubmed/37554676 http://dx.doi.org/10.4103/JCAS.JCAS_128_21 Text en Copyright: © 2023 Journal of Cutaneous and Aesthetic Surgery https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Prathibha, Jantikolalu Parameswarappa
Varghese, Nidhin
Aithal, Vijay Venkatraj
Intralesional Vitamin D3 Versus Bleomycin for Difficult-to-Heal Palmoplantar Warts: A Comparative Study
title Intralesional Vitamin D3 Versus Bleomycin for Difficult-to-Heal Palmoplantar Warts: A Comparative Study
title_full Intralesional Vitamin D3 Versus Bleomycin for Difficult-to-Heal Palmoplantar Warts: A Comparative Study
title_fullStr Intralesional Vitamin D3 Versus Bleomycin for Difficult-to-Heal Palmoplantar Warts: A Comparative Study
title_full_unstemmed Intralesional Vitamin D3 Versus Bleomycin for Difficult-to-Heal Palmoplantar Warts: A Comparative Study
title_short Intralesional Vitamin D3 Versus Bleomycin for Difficult-to-Heal Palmoplantar Warts: A Comparative Study
title_sort intralesional vitamin d3 versus bleomycin for difficult-to-heal palmoplantar warts: a comparative study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405549/
https://www.ncbi.nlm.nih.gov/pubmed/37554676
http://dx.doi.org/10.4103/JCAS.JCAS_128_21
work_keys_str_mv AT prathibhajantikolaluparameswarappa intralesionalvitamind3versusbleomycinfordifficulttohealpalmoplantarwartsacomparativestudy
AT varghesenidhin intralesionalvitamind3versusbleomycinfordifficulttohealpalmoplantarwartsacomparativestudy
AT aithalvijayvenkatraj intralesionalvitamind3versusbleomycinfordifficulttohealpalmoplantarwartsacomparativestudy